Market Overview

UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Isis Pharmaceuticals

Share:
Related ISIS
ISIS Pharma Still Undervalued, Needham Says
Highlights From ISIS Pharmaceuticals At Goldman Sachs Healthcare Conference
Sector's Smaller Players Show The Way (Seeking Alpha)

In a report published Wednesday, Piper Jaffray & Co. reiterated its Overweight rating on Isis Pharmaceuticals (NASDAQ: ISIS), and raised its price target from $15.00 to $18.00.

Piper Jaffray noted, “ISIS is the leading antisense company with a rich pipeline of drugs in development. The primary driver for ISIS shares remains KYNAMRO with European approval this year and a January 29, 2013 PDUFA date. While ISIS shares have risen considerably since May 1st, we look for continued upside driven by KYNAMRO approval, clinical data read-outs and new partnerships. ISIS remains a Top Pick for 2H:12.”

Isis Pharmaceuticals closed Tuesday at $13.74.

Latest Ratings for ISIS

DateFirmActionFromTo
Jun 2015NeedhamReiteratesBuy
Jun 2015JP MorganMaintainsNeutral
Mar 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Price Target Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters